Order Article Reprints

Koralkova P, Belickova M, Kundrat D, Dostalova Merkerova M, Krejcik Z, Szikszai K, Kaisrlikova M, Vesela J, Vyhlidalova P, Stetka J, et al. Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34⁺ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients. Cancers. 2021; 13(9):2161. https://doi.org/10.3390/cancers13092161

Koralkova, Pavla, Monika Belickova, David Kundrat, Michaela Dostalova Merkerova, Zdenek Krejcik, Katarina Szikszai, Monika Kaisrlikova, Jitka Vesela, Pavla Vyhlidalova, Jan Stetka, and et al. 2021. "Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34⁺ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients" Cancers 13, no. 9: 2161. https://doi.org/10.3390/cancers13092161

Koralkova, P., Belickova, M., Kundrat, D., Dostalova Merkerova, M., Krejcik, Z., Szikszai, K., Kaisrlikova, M., Vesela, J., Vyhlidalova, P., Stetka, J., Hlavackova, A., Suttnar, J., Flodr, P., Stritesky, J., Jonasova, A., Cermak, J., & Divoky, V. (2021). Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34⁺ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients. Cancers, 13(9), 2161. https://doi.org/10.3390/cancers13092161